| pubmed-article:15905308 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15905308 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15905308 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:15905308 | lifeskim:mentions | umls-concept:C0030231 | lld:lifeskim |
| pubmed-article:15905308 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:15905308 | lifeskim:mentions | umls-concept:C1519031 | lld:lifeskim |
| pubmed-article:15905308 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15905308 | pubmed:dateCreated | 2005-7-25 | lld:pubmed |
| pubmed-article:15905308 | pubmed:abstractText | Metronomic chemotherapy-the chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule of administration at close regular intervals, with no prolonged drug-free breaks-is a potentially novel approach to the control of advanced cancer disease. It is thought to work primarily through antiangiogenic mechanisms and has, as an advantage, the property of significantly reducing undesirable toxic side-effects. The aim of the present study was to evaluate the cost effectiveness of cyclophosphamide-methotrexate 'metronomic' chemotherapy in the palliative treatment of pretreated metastatic breast cancer. | lld:pubmed |
| pubmed-article:15905308 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15905308 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15905308 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15905308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15905308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15905308 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15905308 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15905308 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:Del TaccaMM | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:KerbelR SRS | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:LiguoriVV | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:FalconeAA | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:EmmeneggerUU | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:BocciGG | lld:pubmed |
| pubmed-article:15905308 | pubmed:author | pubmed-author:TuccoriMM | lld:pubmed |
| pubmed-article:15905308 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15905308 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:15905308 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15905308 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15905308 | pubmed:pagination | 1243-52 | lld:pubmed |
| pubmed-article:15905308 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:meshHeading | pubmed-meshheading:15905308... | lld:pubmed |
| pubmed-article:15905308 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15905308 | pubmed:articleTitle | Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. | lld:pubmed |
| pubmed-article:15905308 | pubmed:affiliation | Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Via Roma, Pisa, Italy. g.bocci@med.unipi.it | lld:pubmed |
| pubmed-article:15905308 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15905308 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15905308 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15905308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15905308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15905308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15905308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15905308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15905308 | lld:pubmed |
